We bring together innovators and investors to commercialise the companies that will form the longevity economy.
There are already 100+ rejuvenation biotechs working on unique therapies and building R&D pipelines to increase healthspan and lifespan.
At the same time, all around the world, innovators are releasing nanobots, reprogramming nerve signals and applying AI to create exciting and scalable contributions to human Longevity.
Longevity science is here; so are the risks and so are the rewards.
We look beyond rejuvenation therapies to embrace other technologies that participate in the Longevity investment category: Agetech, xeno, biomarkers, AI, bioprinting, neuroceuticals, GRAS supplements …
There are multiple technologies that contribute to the reduction of morbidity and the extension of lifespan.